Clinical trial
Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus…
NCT00446134 · Bausch Health Americas, Inc., Industry · Completed
Key facts
| NCT number | NCT00446134 |
|---|---|
| Title | Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV) |
| Official title | Phase 2 Comparison of Weight-based Doses of Taribavirin Combined With Peginterferon Alfa-2b Versus Ribavirin Combined With Peginterferon Alfa-2b in Therapy-naïve Patients With Chronic Hepatitis C Virus Genotype 1 Infection |
| Lead sponsor | Bausch Health Americas, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | Taribavirin, Ribavirin |
| Enrollment | 278 |
| Start date | Mar 1, 2007 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Mar 12, 2007 |
| Last update posted | Jul 27, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: